Manteio Capital’s CytomX Therapeutics CTMX Stock Holding History

Manteio Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,067	Closed	-$65K	–	48
2021 Q4	$65K	Buy	+15,067	New	+$88.3K	0.08%	238

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Manteio Capital's CTMX Position: Q1 2022 in Review

Manteio Capital sold out of CytomX Therapeutics (CTMX) in Q1 2022, closing a stake of 15,067 shares — an estimated $65K sold.

Manteio Capital first reported a position in CTMX in Q4 2021 and held it in 1 quarter. The position peaked at $65K in Q4 2021. 119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

Manteio Capital reported no remaining CytomX Therapeutics position as of Q1 2022 after selling out during the quarter.
Manteio Capital sold 15,067 CytomX Therapeutics shares in Q1 2022, an estimated $65K.
Manteio Capital first reported a position in CytomX Therapeutics in Q4 2021 and held it in 1 quarter.
Manteio Capital's CytomX Therapeutics position peaked at $65K in Q4 2021.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Manteio Capital's 13F filing for Q1 2022.